oncology
Lung Cancer

Pembrolizumab indication reversed after accelerated approval for SCLC

Pembrolizumab has been withdrawn from treatment of metastatic SCLC in the US after post-marketing data failed to confirm the early study benefits that won it FDA accelerated approval two years ago. Merck, in consultation with the FDA, has voluntarily withdrawn its anti-PD-1 therapy (Keytruda) for the treatment of patients with metastatic small cell lung cancer ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic